Drug Trial Radar · NCT01578499
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Jun 11, 2012
Primary completion
May 31, 2016
Study completion Jul 6, 2018
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Seagen Inc.
- First posted
- Apr 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \]compared to that achieved with therapy in the control arm.
Conditions
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Mycosis Fungoides
- Cutaneous T-Cell Lymphoma
Interventions
Brentuximab VedotinDrug
Brentuximab vedotin intravenous injection.
MethotrexateDrug
Methotrexate tablets.
BexaroteneDrug
Bexarotene tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)Time frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
Locations
41 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Hackensack, New Jersey
Site not named
New York, New York
Site not named
Pittsburgh, Pennsylvania
Site not named
Houston, Texas
Site not named
East Melbourne, Australia
Site not named
Concord, New South Wales, Australia
Site not named
South Brisbane, Queensland, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Nedlands, Western Australia, Australia
Site not named
Sankt Pölten, Austria
Site not named
Vienna, Austria
Site not named
Leuven, Belgium
Site not named
São Paulo, Brazil
Site not named
Nantes, France
Site not named
Paris, France
Site not named
Pessac, France
Site not named
Pierre-Bénite, France
Site not named
Reims, France
Site not named
Kiel, Germany
Site not named
Krefeld, Germany
Site not named
Mainz, Germany
Site not named
Mannheim, Germany
Site not named
Minden, Germany
Site not named
Würzburg, Germany
Site not named
Bologna, Italy
Site not named
Florence, Italy
Site not named
Meldola, Italy
Site not named
Warsaw, Poland
Site not named
Barcelona, Spain
Site not named
Madrid, Spain
Site not named
Pamplona, Navarre, Spain
Site not named
Zurich, Switzerland
Site not named
Birmingham, United Kingdom
Site not named
Glasgow, United Kingdom
Site not named
London, United Kingdom
Site not named
Manchester, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.